All In Biotech

Drug Trial Radar · NCT04895722

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 302 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

302

Actual

Start

Jun 25, 2021

Primary completion

May 21, 2025

Study completion Aug 7, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

Conditions

  • Colorectal Cancer

Interventions

  • PembrolizumabBiological

    400 mg or 200 mg pembrolizumab administered via IV infusion.

  • Pembrolizumab/QuavonlimabBiological

    Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.

  • Pembrolizumab/FavezelimabBiological

    Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion

  • Pembrolizumab/VibostolimabBiological

    Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion

  • MK-4830Biological

    800 mg MK-4830 administered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 46 months

Locations

109 sites in 22 countries. Site status is shown where the registry gives one.

  • Mid Florida Cancer Center ( Site 1519)

    Orange City, Florida

  • University Cancer & Blood Center, LLC ( Site 1521)

    Athens, Georgia

  • University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P

    Chicago, Illinois

  • Icahn School of Medicine at Mount Sinai ( Site 1528)

    New York, New York

  • Hematology Oncology Associates of Rockland ( Site 1525)

    Nyack, New York

  • UPMC Hillman Cancer Center ( Site 1516)

    Pittsburgh, Pennsylvania

  • The West Clinic, PLLC dba West Cancer Center ( Site 1576)

    Germantown, Tennessee

  • Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1509)

    Nashville, Tennessee

  • UT Southwestern Medical Center ( Site 1551)

    Dallas, Texas

  • Baylor Scott & White Medical Center - Temple-Division of Hematology/Oncology ( Site 1549)

    Temple, Texas

  • Northwest Medical Specialties, PLLC ( Site 1546)

    Tacoma, Washington

  • UZ Brussel ( Site 0105)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • Cliniques universitaires Saint-Luc-Medical Oncology ( Site 0104)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0102)

    Yvoir, Namur, Belgium

  • UZ Leuven ( Site 0101)

    Leuven, Vlaams-Brabant, Belgium

  • AZ Delta vzw ( Site 0106)

    Roeselare, West-Vlaanderen, Belgium

  • The Moncton Hospital-Oncology ( Site 0307)

    Moncton, New Brunswick, Canada

  • Sunnybrook Research Institute - Odette Cancer Centre ( Site 0316)

    Toronto, Ontario, Canada

  • McGill University Health Centre-CIM - Oncology ( Site 0306)

    Montreal, Quebec, Canada

  • Instituto de Cancerología ( Site 1610)

    Medellín, Antioquia, Colombia

  • Fundación Colombiana de Cancerología Clínica Vida ( Site 1606)

    Medellín, Antioquia, Colombia

  • Clinica de la Costa S.A.S. ( Site 1608)

    Barranquilla, Atlántico, Colombia

  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 1611)

    Bogotá, Bogota D.C., Colombia

  • Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1601)

    Valledupar, Cesar Department, Colombia

  • Oncomédica S.A.S ( Site 1602)

    Montería, Departamento de Córdoba, Colombia

  • Mediservis del Tolima IPS S.A.S ( Site 1609)

    Ibague, Tolima Department, Colombia

  • CIMCA-Hemato-Oncology ( Site 2101)

    San José, Provincia de San José, Costa Rica

  • Hospital Metropolitano - Sede Lindora-Metropolitano Research Institute Sede Lindora ( Site 2102)

    Santa Ana, Provincia de San José, Costa Rica

  • Rigshospitalet ( Site 1904)

    Copenhagen, Capital Region, Denmark

  • Regionshospitalet Gødstrup ( Site 1901)

    Herning, Central Jutland, Denmark

  • Aalborg Universitetshospital, Syd ( Site 1903)

    Aalborg, North Denmark, Denmark

  • Odense Universitetshospital ( Site 1902)

    Odense, Region Syddanmark, Denmark

  • North Estonia Medical Centre Foundation-Chemotherapy ( Site 2301)

    Tallinn, Harju, Estonia

  • Tartu University Hospital ( Site 2302)

    Tartu, Tartu, Estonia

  • Hôpital Saint Antoine-Oncologie médicale ( Site 0508)

    Paris, France

  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service d'Hepato-Gastro-Enterologie et

    Marseille, Bouches-du-Rhone, France

  • Centre Georges François Leclerc ( Site 0506)

    Dijon, Cote-d Or, France

  • CHU Rangueil-Digestive oncology department ( Site 0502)

    Toulouse, Haute-Garonne, France

  • Hopital Claude Huriez - CHU de Lille ( Site 0510)

    Lille, Nord, France

  • Centre Hospitalier Universitaire de Poitiers ( Site 0511)

    Poitiers, Vienne, France

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.